Severity
Critical
FDA Drug recall · Reported December 6, 2023
Marketed Without an Approved NDA/ANDA: products found to contain undeclared diclofenac.
Botanical Be recalled Artri King Reforzado con Origa y Omega 3 tablets, packaged in 100-count bottles, Manufact… - a critical-severity action.
Artri King Reforzado con Origa y Omega 3 tablets, packaged in 100-count bottles, Manufact… was recalled by Botanical Be in December 6, 2023. Reason: Marketed Without an Approved NDA/ANDA: products found to contain undeclared diclofenac.. Check the official notice for the remedy. Verify recall #D-0224-2024 with the FDA Drug before acting.
The recall
Botanical Be issued this critical-severity FDA Drug recall-Marketed Without an Approved NDA/ANDA: products found to contain undeclared diclofenac..
Sourced from official FDA Drug enforcement records. Verify recall #D-0224-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0224-2024) was formally reported on December 6, 2023, with the manufacturer initiating the action on October 20, 2023. It is classified under Critical severity (Class I), with a current status of Ongoing. Botanical Be is listed as the recalling firm, operating out of El Paso, TX. Federal records list the affected scope as 235 bottles.
The documented reason for this recall is: Marketed Without an Approved NDA/ANDA: products found to contain undeclared diclofenac. Distribution data in the federal record shows the product reached: USA Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 2,002 dietary supplements recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Critical
Affected scope
235 bottles
Related Recalls
6
0 from same agency
Artri King Reforzado con Origa y Omega 3 tablets, packaged in 100-count bottles, Manufactured by: Plantas medicinales de Mexico, Melchol Ocampo # 65 Local D, Delegacion Xochimilco CP 16800, Mexico DF, UPC 7 501031 111138
Marketed Without an Approved NDA/ANDA: products found to contain undeclared diclofenac.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Critical (Class I) |
| Status | Ongoing |
| Recall number | D-0224-2024 |
| Date reported | December 6, 2023 |
| Date initiated | October 20, 2023 |
| Recalling firm | Botanical Be |
| Firm location | El Paso, TX |
| Affected scope | 235 bottles |
| Distribution | USA Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Pure Vitamins and Natural Supplements, LLC · 2026-04-15
Pure Vitamins and Natural Supplements, LLC · 2026-04-15
Herbal Creations USA · 2026-04-01
Winder Laboratories, LLC · 2026-03-25
Imu-Tek Animal Health, Incorporated · 2026-02-11
Compare this recall with Blue Bull Extreme Male Enhancement Supplement, total of 15 … →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported December 6, 2023. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.